| |
3F Model generationa
|
3F Model selectionb
|
---|
drug
|
# 3F Models
|
# lower SBC
|
# lower AIC
|
lower SBC
c
|
lower AIC
d
|
N test
|
ase
|
3F model selected
e
|
Nucleoside RT inhibitorsf
|
AZT
|
300
|
86
|
0
|
yes
|
no
|
800
|
0.103
|
296
|
|
3TC
|
150
|
60
|
34
|
yes
|
no
|
807
|
0.037
|
99
|
|
ddI
|
150
|
20
|
70
|
no
|
yes
|
807
|
0.049
|
83
|
|
d4T
|
120
|
41
|
35
|
yes
|
no
|
806
|
0.040
|
81
|
|
ABC
|
200
|
111
|
53
|
yes
|
no
|
807
|
0.038
|
95
|
|
FTC
|
80
|
28
|
22
|
yes
|
yes
|
804
|
0.071
|
76
|
|
TDF
|
400
|
66
|
196
|
no
|
yes
|
807
|
0.039
|
298
|
NNRTIg
|
NVP
|
400
|
93
|
0
|
yes
|
no
|
801
|
0.089
|
391
|
|
EFV
|
500
|
101
|
0
|
yes
|
no
|
807
|
0.246
|
386
|
|
ETR
|
700
|
49
|
0
|
yes
|
no
|
777
|
0.113
|
656
|
Protease inhibitors
|
IDV
|
485
|
50
|
51
|
yes
|
yes
|
805
|
0.075
|
482
|
|
NFV
|
375
|
64
|
6
|
yes
|
yes
|
808
|
0.063
|
375
|
|
SQV
|
600
|
53
|
0
|
yes
|
no
|
807
|
0.092
|
575
|
|
APV
|
1000
|
0
|
656
|
no
|
yes
|
808
|
0.060
|
709
|
|
LPV
|
500
|
205
|
28
|
yes
|
no
|
807
|
0.157
|
319
|
|
ATV
|
1275
|
0
|
2
|
no
|
yes
|
805
|
0.117
|
1158h
|
|
TPV
|
1000
|
641
|
142
|
yes
|
no
|
806
|
0.059
|
428
|
|
DRV
|
1000
|
823
|
799
|
yes
|
yes
|
816
|
0.096
|
707
|
- aThe number of 3F models generated was arbitrary but taken large enough such that at least one 3F model was found with a lower SBC or AIC than the reference on the genotype-phenotype data set up to July 2006.
- bFrom the remaining 3F models with lower SBC or AIC than the reference, the 3F model was then selected with the lowest average squared error (ase) on an unseen genotype-phenotype data set collected between July and September 2006 (test set) containing approximately 800 samples.
- cSBC of the selected 3F model < SBC reference on the test set (yes/no).
- dAIC of the selected 3F model < AIC reference on the test set (yes/no).
- eThe number of different random divisions used in the stepwise regression in the selected 3F model.
- fFor the nucleoside RT inhibitors the number of random divisions needed was less than 100, with exception of AZT and TDF.
- gFor the non-nucleoside RT inhibitors most random divisions were needed for ETR.
- hATV was the only drug for which more than 1000 different random divisions were needed.